Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARVN 
Arvinas Inc (ARVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ARVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $18.31
1 Year Target Price $18.31
| 9 | Strong Buy |
| 4 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.31% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 708.18M USD | Price to earnings Ratio - | 1Y Target Price 18.31 |
Price to earnings Ratio - | 1Y Target Price 18.31 | ||
Volume (30-day avg) 21 | Beta 2.48 | 52 Weeks Range 5.90 - 28.70 | Updated Date 11/6/2025 |
52 Weeks Range 5.90 - 28.70 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-10-28 | When Before Market | Estimate -0.76 | Actual -0.48 |
Profitability
Profit Margin -18.73% | Operating Margin (TTM) -104.54% |
Management Effectiveness
Return on Assets (TTM) -6.35% | Return on Equity (TTM) -10.17% |
Valuation
Trailing PE - | Forward PE 17.7 | Enterprise Value -170718895 | Price to Sales(TTM) 2.27 |
Enterprise Value -170718895 | Price to Sales(TTM) 2.27 | ||
Enterprise Value to Revenue 5.69 | Enterprise Value to EBITDA -1.62 | Shares Outstanding 70817595 | Shares Floating 27980700 |
Shares Outstanding 70817595 | Shares Floating 27980700 | ||
Percent Insiders 6.89 | Percent Institutions 91.11 |
Upturn AI SWOT
Arvinas Inc
Company Overview
History and Background
Arvinas Inc. was founded in 2013 based on the work of Dr. Craig Crews at Yale University. It pioneered PROTAC (proteolysis-targeting chimera) technology for targeted protein degradation. The company has focused on developing novel therapeutics for oncology and other diseases.
Core Business Areas
- Oncology: Focused on developing PROTAC-based therapies for various cancers, including prostate cancer and breast cancer.
- Neuroscience: Exploring the application of PROTAC technology to address neurological disorders.
Leadership and Structure
Arvinas is led by John Houston, Ph.D., as President and CEO. The company has a board of directors and operates with a functional organizational structure, including research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- Bavdegalutamide (ARV-110): An investigational PROTAC degrader targeting the androgen receptor (AR) in metastatic castration-resistant prostate cancer (mCRPC). It's in Phase 3 clinical trials. Competitors include androgen receptor inhibitors like enzalutamide (Xtandi, manufactured by Astellas and Pfizer) and abiraterone acetate (Zytiga, manufactured by Johnson & Johnson). Market share data not yet available as product is not approved.
- ARV-471: An investigational PROTAC estrogen receptor (ER) degrader being developed for the treatment of ER-positive/HER2-negative breast cancer. It is in Phase 3 clinical trials. Competitors include selective estrogen receptor degraders (SERDs) like fulvestrant (Faslodex, AstraZeneca) and selective estrogen receptor modulators (SERMs) like tamoxifen. Market share data not yet available as product is not approved.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the oncology and neurodegenerative disease segments, is characterized by high growth potential, intense competition, and stringent regulatory requirements. Targeted protein degradation is an emerging field with potential to address previously undruggable targets.
Positioning
Arvinas is a leader in the PROTAC-based targeted protein degradation field. Its competitive advantage lies in its first-mover status and extensive intellectual property portfolio in this technology area.
Total Addressable Market (TAM)
The TAM for oncology and neurodegenerative disease therapies is very large, potentially exceeding hundreds of billions of dollars. Arvinas, with its novel PROTAC technology, is positioned to capture a significant share of this market if its therapies are successful in clinical trials and approved.
Upturn SWOT Analysis
Strengths
- Pioneering PROTAC technology
- Strong intellectual property portfolio
- Experienced leadership team
- Advancing clinical pipeline
Weaknesses
- Reliance on novel technology with inherent risks
- High cash burn rate due to R&D expenses
- Dependence on clinical trial success
- Currently no commercial products
Opportunities
- Expanding PROTAC technology to new therapeutic areas
- Partnering with larger pharmaceutical companies
- Gaining regulatory approval for lead candidates
- Developing next-generation PROTACs
Threats
- Clinical trial failures
- Competition from other targeted protein degradation approaches
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- KYTH
- MRTX
- LLY
Competitive Landscape
Arvinas faces competition from established pharmaceutical companies developing traditional therapies and other companies exploring targeted protein degradation. Arvinas's advantage is its focus on PROTACs, but it must demonstrate the clinical superiority of its approach.
Growth Trajectory and Initiatives
Historical Growth: Arvinas has experienced growth in terms of its pipeline and partnerships.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing bavdegalutamide and ARV-471 into Phase 3 trials, expanding partnerships, and exploring new PROTAC targets.
Summary
Arvinas is a pioneering biopharmaceutical company specializing in PROTAC technology for targeted protein degradation. Its focus on novel therapies for cancer and other diseases positions it for significant growth if clinical trials are successful. The company is navigating a competitive landscape and relies heavily on R&D. It needs to manage cash flow and mitigate risks associated with novel technology. Recent advancement of Bavdegalutamide and ARV-471 to phase 3 trails is a promising sign.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Arvinas Inc. Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
- Company press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data is based on current estimates and may be subject to change. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arvinas Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-09-27 | Chairperson, CEO & President Dr. John G. Houston Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 430 | Website https://www.arvinas.com |
Full time employees 430 | Website https://www.arvinas.com | ||
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.